


UConn Stamford Student Managed Fund  
Spring 2025  
Portfolio Snapshot: Team Green


Team Green's Relative Performance to S&P 500			
S&P 500		TEAMS RETURN	
Beginning Value	\$ 5625.81	Beginning Value	\$ 551,133.47
Current Value	\$ 5282.70	Current Value	\$ 553,543.36
% Change	-6.10%	% Change	0.44%
Difference In Performance		6.54%	
S&P 500 Beta:	1.00	Team Green Beta:	0.84



Portfolio Allocation

Team Green Portfolio Overview									
Company	# of Shares	Avg. Fill Price	Current Price	Purchase Cost	Current Value	Weight	Total P/L	HPY%	
DIAGEO PLC (XNYS:DEO)	0.00	\$ 137.43	\$ 109.58	\$ 34,357.50	\$ -	0.00%	\$ (910.00)	-3%	
VISA INC. (XNYS:V)	120.42	\$276.78	\$ 329.61	\$ 33,329.46	\$ 39,691.17	7.17%	\$ 6,361.71	19%	
AMAZON.COM, INC. (XNAS:AMZN)	0.00	\$ 185.99	\$ 172.61	\$ 45,009.58	\$ -	0.00%	\$ 8,685.38	16%	
ZOETIS INC. (XNYS:ZTS)	0.96	\$182.35	\$ 148.67	\$ 175.31	\$ 142.93	0.03%	\$ (7,783.70)	-18%	
ALPHABET INC. (XNAS:GOOG)	217.33	\$168.86	\$ 153.36	\$ 36,697.82	\$ 33,007.33	5.96%	\$ (3,690.49)	-10%	
THE HERSHEY COMPANY (XNYS:HSY)	1.38	\$181.46	\$ 166.59	\$ 249.83	\$ 229.36	0.04%	\$ (6,423.67)	-20%	
CHENIERE ENERGY PARTNERS UNT (XNYS:CQP)	474.75	\$55.31	\$ 60.86	\$ 26,258.33	\$ 28,893.19	5.22%	\$ 3,584.85	10%	
WASTE MANAGEMENT, INC. (XNYS:WM)	201.65	\$216.32	\$ 230.91	\$ 43,619.85	\$ 46,729.14	8.44%	\$ 3,109.29	7%	
BROADRIDGE FINANCIAL SOLUTIONS, INC. (XNYS:BRD)	253.00	\$237.73	\$ 235.85	\$ 60,145.69	\$ 59,885.00	10.82%	\$ (260.69)	0%	
NIKE, INC. (XNYS:NKE)	4.0763	\$74.87	\$ 55.76	\$ 305.19	\$ 227.29	0.04%	\$ (11,625.26)	-26%	
MICROSOFT CORPORATION (XNAS:MSFT)	133.29	\$415.44	\$ 367.78	\$ 55,373.37	\$ 49,020.84	8.86%	\$ (6,352.53)	-11%	
CME GROUP INC. (XNAS:CME)	225.00	\$241.43	\$ 262.53	\$ 54,321.75	\$ 59,351.21	10.72%	\$ 5,029.46	9%	
CHARLES RIVER LABORATORIES INTERNATIONAL	0.00	\$155.92	\$ 106.05	\$ -	\$ -	0.00%	\$ (7,740.91)	-36%	
Philip Morris International Inc. (XNYS:PM)	222.00	\$148.10	\$ 163.21	\$ 32,878.20	\$ 36,552.63	6.60%	\$ 3,674.43	11%	
Schlumberger N.V. (XNYS:SLB)	0.00	\$42.94	\$ 35.11	\$ -	\$ -	0.00%	\$ (2,151.72)	-18%	
AMERICAN TOWER CORPORATION (XNYS:AMT)	109.00	\$212.41	\$ 222.66	\$ 23,152.69	\$ 24,269.94	4.38%	\$ 1,117.25	5%	
EQUIFAX INC. (XNYS:EFX)	45.00	\$242.46	\$ 221.25	\$ 10,910.70	\$ 9,956.25	1.80%	\$ (954.45)	-9%	
FMC CORPORATION (XNYS:FMC)	426.00	\$41.22	\$ 37.84	\$ 17,559.72	\$ 16,367.97	2.96%	\$ (1,191.75)	-7%	
ADOBE INC. (XNAS:ADBE)	0.00	\$439.16	\$ 348.80	\$ -	\$ -	0.00%	\$ (4,581.50)	-20%	
COMCAST CORPORATION (XNAS:CMCSA)	643.00	\$36.76	\$ 34.01	\$ 23,636.68	\$ 21,868.43	3.95%	\$ (1,768.25)	-7%	
ABBOTT LABORATORIES (XNYS:ABT)	218.00	\$131.85	\$ 130.98	\$ 28,743.30	\$ 28,553.64	5.16%	\$ (189.66)	-1%	
VAIL RESORTS, INC. (XNYS:MTN)	200.00	\$140.27	\$ 138.43	\$ 28,054.00	\$ 27,686.00	5.00%	\$ (368.00)	-1%	
Sel Sector:Util SPDR (ARCX:XLU)	216.00	\$77.92	\$ 77.77	\$ 16,830.72	\$ 16,798.32	3.03%	\$ (32.40)	0%	
SPDR S&P 500 (ARCX:SPY)	102.54	\$38.69	\$ 526.41	\$ 55,238.67	\$ 53,979.45	9.75%	\$ (1,259.22)	-2%	
CASH (USD)					\$ 333.26	0.06%			
Beg. Balance				\$ 551,133.47	\$ 553,543.36	100.00%	\$ (25,721.82)	0.44%	

Current Allocation Of Funds



		Valuation (P)		
		Value	Blend	Growth
Market Capitalization (mm) (P)	Large	2	6	2
	Mid	1	1	0
Small	0	0	0	0

	PORTFOLIO	BENCHMARK
Avg. Market Cap (mm)	501,575.79	839,767.24
Dividend Yield	2.50	1.48
EV/EBITDA	17.16	19.45
P/E	22.47	23.82
Forward P/E	24.52	25.72
EBIT Margin %	42.33%	27.92%

Team Green SMF Positions

Co-Lead Managers: Mohammed Ruwaid, Zachary Markovych  
Portfolio Manager: Kevin Jankowski  
Team Advisor: Blake Mather  
Fund Director: Dr. Chinmoy Ghosh

Sector Breakdown

Technology: Kat, Nat, Allen, Mitch  
Healthcare: Sam, Adrien  
Consumer Discretionary: Kevin, Adrien  
Industrials: Zach, Ron  
Consumer Staples: Kevin, Tim

Financials: Mitch, Ron  
Communications: Mo, Tim  
Energy: Kat, Nathaly  
Materials: Zach, Mo  
Real Estate: Kevin, Allen

## VISA (V)



Target Price: \$ 304.00	Purchase Price: \$ 278
Beta: 1.01	P/E: 29.68x
Stop Loss: 20%	Dividend Yield: 0.75%
Portfolio Allocation: 6%	ROIC: 27.37

Performance: **+19.1%**  
Pitch Date: Oct. 14<sup>th</sup>, 2024  
Voting Results: 11/11, Buy  
Analysts: Allen Counts, Mitchell Velasco, Ronaldo Carillo

### Investment Thesis:

- Strong Competitive Advantage- Very Wide Economic Moat
- Track Record of Sustainable Growth
- Platform for Continued Growth
- Highly Diversified Business
- Strong balance sheet



## Alphabet Inc. (GOOGL)

### Alphabet

Target Price: \$206.00	Purchase Price: \$174.29
Beta: 1.04	P/E (TTM): 22.9
Stop Loss: 20%	Dividend Yield: 0.46%
Portfolio Allocation: 4.36%	ROIC: 26.55

Performance: **-10.1%**  
Pitch Date: Nov. 4<sup>th</sup>, 2024  
Voting Results: 8/11, Buy  
Analyst: Mohammed Ruwaid, Tim Cone, Kat Berger

### Investment Thesis:

- Diversified Portfolio: Strong presence in digital advertising, cloud computing, hardware, and AI.
- Wide Economic Moat: Dominates search with over 90% market share.
- ROIC vs. WACC: Alphabet demonstrates a high ROIC of 26.55%, significantly exceeding its WACC of 8.48%.
- Innovation-Driven: Leading in AI and machine learning advancements.
- Global Reach: Expanding influence across multiple high-growth sectors.



## Cheniere Energy Partners (CQP)



Target Price: \$57.15	Purchase Price: \$50
Beta: 0.68	P/E (TTM): 10.84
Stop Loss: 20%	Dividend Yield: 6.67%
Portfolio Allocation: 3.25%	ROIC: 11.36

Performance: **+10%**  
Pitch Date: Nov. 11<sup>th</sup>, 2023  
Voting Results: 11/11, Buy  
Analyst: Kat Berger, Nathaly Herrera

### Investment Thesis:

- Stable Cash Flows: 20-year take-or-pay contracts on roughly 98% of their production provides predictable revenue.
- Low Commodity Price Risk: Very limited exposure to fluctuations in the price of natural gas. CQP operates as a toll-taker, earning fees on every cargo.
- Strong Growth Potential: High returns on invested capital. Plans for Sabine Pass expansion and new contracts should further boost revenue & profits.
- Attractive Return: CQP currently offers a high dividend yield of 6.67%.
- Increased Global Demand: Forecasted 50% rise in global LNG demand by 2040, driven by countries like China and India, seeking to cut carbon emissions by switching from coal to gas.



## Waste Management (WM)



Target Price: \$243.84	Purchase Price: \$217.9
Beta: 0.75	P/E (TTM): 33.3
Stop Loss: 19.15%	Dividend Yield: 1.38%
Portfolio Allocation: 7%	ROIC: 11.13

Performance: **+7.1%**  
Pitch Date: Nov. 18<sup>th</sup>, 2024  
Voting Results: 11/11, Buy  
Analyst: Zach Markovych, Ronaldo Carillo

### Investment Thesis:

- Stable business model in an essential industry. Predictable recurring revenue for the next 10-20 years.
- Wide economic moat rooted in intangible assets (regulatory permits for landfills) and cost advantages (route density).
- Our sales forecast is conservative compared to management guidance & analyst consensus of 6-7% growth. We assume organic top-line growth of about 5% as pricing moderates, and another 50-80 basis points on top from acquisitions.
- Our DCF does not forecast any margin expansion, taking into consideration industry cyclicality, potential margin headwinds from lower landfill volumes, dilutive acquisitions, and so on.
- Our exit multiple also represents a drop from current levels, closer to the historic average.



## Broadridge Financial Solutions (BR)



Target Price: \$269	Purchase Price: \$237.73
Beta: 1.07	P/E: 41.09x
Stop Loss: 18.84%	Dividend Yield: 1.5%
Portfolio Allocation: 10%	ROIC: 13.19

Performance: **-0.4%**  
Pitch Date: Jan 29<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Zach Markovych, Mohammed Ruwaid

### Investment Thesis:

- **Market Leader:** Broadridge processes communication and proxy voting for over 80% of outstanding shares
- **70% Recurring Revenue:** High mix of recurring sales provides predictability & certainty
- **Customer Retention:** The company boasts a 98% client revenue retention rate
- **High Profitability:** ~100% Free cash flow conversion and mid-to-high teen ROIC
- **Recession Resistant:** During the financial crisis, equity proxy positions declined only 2% Corporations and mutual funds will always need to report results and hold shareholder votes
- **Growth Guidance:** 7-9% recurring revenue growth (5-8% organic + acquisitions)  
8-12% steady and consistent EPS growth.  
Adjusted operating margin expansion >50bps



## Microsoft (MSFT)



Target Price: \$500	Purchase Price: \$415.52
Beta: .91	P/E: 36.8x
Stop Loss: 19%	Dividend Yield: .75%
Portfolio Allocation: 10%	ROIC: 29.36

Performance: **-11.5%**  
Pitch Date: Feb 3<sup>rd</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Kat Berger, Nathaly Herrera

### Investment Thesis:

- **Wide Moat:** Microsoft has a wide economic moat due to its strong brand recognition, extensive ecosystem, and significant investments in research and development.
- **Strong ROIC:** Microsoft has a return on invested capital (ROIC) of 29.36% in 2024, reflecting efficient capital allocation and strong profitability across its diverse business segments.
- **Diversified Revenue Streams:** Strong across cloud (Azure), enterprise software (Office 365), gaming (Xbox), and LinkedIn, reducing reliance on any single segment.
- **Attractive Valuation:** DCF forecasts a stable growth rate in 13%-14% range and a 25.57% margin of safety, providing a buffer against market volatility and economic uncertainty.



## NIKE (NKE)



Target Price: \$89.05	Purchase Price: \$74.86
Beta: 1.03	P/E: 23.73x
Stop Loss: 20%	Dividend Yield: 2.08%
Portfolio Allocation: 8%	ROIC: 20.17

Performance: **-25.5%**  
Pitch Date: Feb 3<sup>rd</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Kevin Jankowski, Adrien Vincent

### Investment Thesis:

- Strategic Leadership by CEO Elliott Hill enhances global strategies and market reach.
- Targeting significant growth in Asia through more digital sales and an expanding middle-class demanding for premium sportswear.
- Enhanced Direct-to-Consumer channels and continuous product innovation aim to boost market share and engagement.
- Capital efficiency demonstrated with a ROIC of 20.17% significantly exceeding the WACC of 8.7%.
- Focus on high-margin markets expected to bring back EBIT margins to mid-teen levels.
- Investments in sustainability and innovative technologies like Flyknit and self-lacing shoes strengthen competitive edge.



## CME Group Inc (CME)



Target Price: \$268	Purchase Price: \$241.43
Beta: 0.45	P/E: 25.77x
Stop Loss: 20%	Dividend Yield: 4.41%
Portfolio Allocation: 10%	ROIC: 9.4

Performance: **+9%**  
Pitch Date: Feb 10<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Allen Counts, Mitchell Velasco

### Investment Thesis:

- Strong pricing power derived from customer lock-in effects and exclusive nature of contract offerings
- Expectation for continued long-term growth in ADV stemming from increased retail participation around the globe, Short-term boost from recent and expected market volatility
- Nearly 100% margin on incremental product offerings provides significant leverage for earnings growth from expansion, operational expenses anticipated to fall from increased tech adoption
- The company is well positioned to extend their consistent FCF growth rates, stemming from increased FCF conversion rates and margin expansion
- Defensive in nature, as CME group often sees increased revenues during periods of high volatility, including recessions



# Philip Morris International (PM)



Target Price: \$183	Purchase Price: \$148.10
Beta: 0.49	P/E: 24.03x
Stop Loss: 20%	Dividend Yield: 3.74%
Portfolio Allocation: 6%	ROIC: 22.17

Performance: +10%  
Pitch Date: Feb 11<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Kevin Jankowski

## Investment Thesis:

- **Market Leader:** PMI continues to dominate the nicotine and smoke-free markets, with IQOS leading the heat-not-burn category and ZYN maintaining market leadership in nicotine pouches.
- **Strong Recurring Revenue:** The smoke-free business now accounts for 40% of total net revenue, ensuring long-term growth and stability.
- **Customer Retention & Expansion:** With 38.6 million estimated adult users of smoke-free products, PMI benefits from loyal customers and expanding market penetration.
- **High Profitability & Cash Flow:** PMI's pricing power and cost efficiencies drive strong cash flow conversion, supporting sustained profitability and margin expansion.
- **Resilient Business Model:** PMI has demonstrated strong financial performance even in volatile economic conditions, as tobacco and nicotine consumption remains stable.
- **Growth Outlook:** PMI projects 7-9% revenue growth driven by double-digit expansion in smoke-free products and continued pricing strategies. Adjusted operating margins are expected to expand by more than 50 basis points.
- **Strong ROIC:** 22.17%, however historically was much higher in the mid-40's



# American Tower Corporation (AMT)



Target Price: \$215	Purchase Price: \$205
Beta: 0.88	P/E: 27.8x
Stop Loss: 20%	Dividend Yield: 3.18%
Portfolio Allocation: 2%	ROIC: 6.94

Performance: +4%  
Pitch Date: March 3<sup>rd</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Kevin Jankowski, Allen Counts

## Investment Thesis:

- **Market Leader:** American Tower is a global leader in telecommunications infrastructure, operating over 220,000 tower sites across 25+ countries to support 5G expansion, data consumption growth, and mobile connectivity demands.
- **Strong Recurring Revenue:** The company generates over 98% of its revenue from long-term tenant leases, ensuring stable cash flow and predictable growth, backed by inflation-linked escalators.
- **Customer Retention & Expansion:** With long-term contracts averaging 5-10 years and relationships with major carriers like AT&T, Verizon, and T-Mobile, American Tower benefits from high customer retention and continued site expansion.
- **Resilient Business Model:** The essential nature of digital infrastructure ensures demand even in economic downturns, making American Tower a defensive, high-quality real estate investment.
- **Growth Outlook:** Projected mid-single-digit revenue growth driven by global 5G rollouts, edge computing expansion, and data center initiatives.
- **The company expects \$54 billion in non-cancelable lease revenue in future periods.** However, lease churn (cancellations or non-renewal) was approximately 2% in 2024, primarily due to T-Mobile lease terminations related to Sprint's network integration.



# Equifax INC. (EFX)



Target Price: \$288.84	Purchase Price: \$242.46
Beta: 1.65	P/E: 50.33x
Stop Loss: 31.6%	Dividend Yield: 0.64%
Portfolio Allocation: 2%	ROIC: 8.76%

Performance: -10%  
Pitch Date: March 3<sup>rd</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Ronaldo Carrillo, Zachary Markovych

## Investment Thesis:

- **Equifax's businesses are capital-light, and incremental revenue tends to flow to the bottom line, generating high free cash flow conversion and margin expansion.**
- **Strong competitive moat** should last many decades into the future - one of the "Big Three"
- **Credit reports are essential** for lenders and are unlikely to be disrupted. Sticky customer relationships provide consistent cash flow and pricing power.
- **Strong growth in the income verification segment** should lead to margin expansion. Also, potential for rebound in mortgage revenues, if rates eventually come down.
- **Firmwide organic revenue growth of 7-10%** according to management guidance.
- **Cloud migration is nearly complete, which will decrease CapEx and boost efficiency/margins.**



# FMC Corporation (FMC)



Target Price: \$84.65	Purchase Price: \$41.22
Beta: 0.85	P/E: 12.9x
Stop Loss: 50%	Dividend Yield: 5.76%
Portfolio Allocation: 3%	ROIC: 12.66

Performance: -8%  
Pitch Date: March 10<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Mohammed Ruwald, Zachary Markovych

## Investment Thesis:

- **Down 67% from 2023** - Investors overly focused on near-term destocking and patent risks.
- **Downside Priced In** - In a downside scenario, we assume inventory destocking continues and FMC's new products fail to fully replace the profitability of its diamides. As a result, revenue growth slows to low single digits and margins contract below current levels. Our fair value estimate in this scenario is \$41 per share.
- **Essential Business** - Without the use of pesticides, there would be a 78% loss of fruit production, a 54% loss of vegetable production, and a 32% loss of cereal production.
- **Industry Growth** - Yield gains are needed to support rising food consumption from emerging markets. As a result, crop chemicals should see strong growth.
- **Strong Pipeline** - FMC's new products should replace lost sales from expiring patents.
- **Biologicals** - New organic products should take market share from synthetic crop chemicals.



# Comcast Corporation (CMCSA)



Target Price: \$52.65	Purchase Price: \$36.75
Beta: 0.94	P/E: 8.61x
Stop Loss: 20%	Dividend Yield: 3.59%
Portfolio Allocation: 5%	ROIC: 8.21

Performance: -9%  
Pitch Date: March 24<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Sam Aguilar, Kat Berger

## Investment Thesis:

- **Strong Market Position in Broadband and Connectivity:** Comcast is the largest broadband provider in the U.S., with a dominant market share in high-speed internet services. As demand for reliable, high-speed internet continues to grow due to increasing remote work, streaming, and connected devices, Comcast is poised to benefit from sustained subscriber growth and pricing power.
- **Diversified Business Model:** The company operates through key segments: Residential Connectivity & Platforms, Business Services (Connectivity, Media, Studio, and Theme Park). This diversification provides multiple revenue streams, reducing reliance on any single business segment and enhancing long-term resilience.
- **Content and Streaming Expansion:** Comcast's extensive content library and its Peacock streaming service provide competitive advantages in the streaming wars. While traditional cable subscriptions decline, Comcast's hybrid approach - leveraging both broadband and streaming - positions it well to capture shifts in consumer behavior.
- **Technological Innovation and Infrastructure Investment:** Comcast continues to invest in next-generation broadband technology, such as fiber and 10G, to improve internet speeds and network efficiency. These investments enhance customer retention and competitive positioning against fiber and 5G competitors.
- **Consistent Free Cash Flow and Shareholder Returns:** Comcast generates strong free cash flow, enabling it to fund capital expenditures, strategic acquisitions, share repurchases, and a growing dividend. The company's disciplined capital allocation strategy supports long-term shareholder value creation.
- **Strategic M&A and Global Expansion:** Comcast has a record of value-enhancing acquisitions, including Sky Group in Europe, expanding its international footprint. Strategic acquisitions could further bolster its content, broadband, and technology capabilities.



# Abbott Laboratories (ABT)



Target Price: \$148.27	Purchase Price: \$131.65
Beta: 0.80	P/E: 17.12x
Stop Loss: 22.46%	Dividend Yield: 1.9%
Portfolio Allocation: 3%	ROIC: 12.42

Performance: -1%  
Pitch Date: March 31<sup>st</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Samuel Aguilar, Ronaldo Carrillo

## Investment Thesis:

- **Diversified Revenue Stream:** Abbott's business model spans multiple healthcare segments, reducing risk and providing stable revenue generation. The company's strong position in medical devices (e.g., FreeStyle Libre glucose monitoring system) and diagnostics (e.g., COVID-19 testing) has been instrumental in sustaining revenue growth.
- **Strong Financial Performance:** Abbott has demonstrated consistent revenue growth, strong margins, and robust free cash flow. The company maintains a healthy balance sheet with non-negative debt levels and a commitment to returning capital to shareholders through dividends and share repurchases.
  - **5-Year Revenue CAGR:** ~5-7%, **EPS Growth (FY19):** 6-10%, **Gross Margin:** ~65-67%, **Operating Margin:** ~20%
- **Growth in Diabetes Care and Medical Devices:** The FreeStyle Libre system has gained significant market share in continuous glucose monitoring (CGM), benefiting from increasing demand due to rising diabetes prevalence worldwide. Abbott's cardiac and neuromuscular device portfolio also contributes to sustained long-term growth.
  - **FreeStyle Libre (Continuous Glucose Monitoring):** A market leader in diabetes management.
  - **Alinity Diagnostics System:** A cutting-edge platform driving efficiency in lab testing.
  - **Stentent Heart Device:** Gaining prevalence in minimally invasive procedures.
- **Expansion in Emerging Markets:** Abbott continues to expand its pharmaceutical and medical businesses in emerging markets, where rising healthcare expenditures and an aging population provide substantial growth opportunities.
  - **Abbott has a strong presence in emerging markets, particularly in Asia, Latin America, and Africa, where healthcare spending is rising.**
- **Emerging Markets Contribution:** ~10-15% of total revenue.
- **Key Growth Drivers:** Increasing healthcare access, rising chronic disease prevalence, aging populations.
- **Commitment to Innovation:** The company invests heavily in research and development (R&D), a steady new product pipeline that drives growth and competitive advantage.



# Vail Resorts INC. (MTN)



Target Price: \$180	Purchase Price: \$140.27
Beta: 0.94	P/E: 20.3x
Stop Loss: 40%	Dividend Yield: 6.23%
Portfolio Allocation: 5%	ROIC: 10.31

Performance: -6%  
Pitch Date: April 14<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Mohammed Ruwald, Zachary Markovych

## Investment Thesis:

- **Vail Resorts is the industry leader** delivering stable and predictable growth.
- **Duopoly position** with pricing power and irreplaceable assets.
- **Up-front subscription revenue** protects earnings from unfavorable weather conditions.
- **Passionate guest base** and high-end vacation travelers.
- **6% dividend + 6% earnings growth** = 12% return (further upside if multiple expands back to historic average)
- **Stock trades at our bear case DCF valuation, reflecting a severe COVID level downturn** that lasts for two years.
- **We assigned a 40% weighting on the bear case** implying very high odds of recession.



## Diageo (DEO)

### DIAGEO

Target Price: \$ 154	Purchase Price: \$ 133
Beta: 0.8	P/E: 19.23x
Stop Loss: 20%	Dividend Yield: 3.03%
Portfolio Allocation: 6%	ROIC: 14.47

Performance: **-2.7%**  
Pitch Date: Sep. 23<sup>rd</sup>, 2024  
Voting Results: 11/11, Buy  
Analysts: Zachary Markovych, Mohammed Ruwaid

#### Investment Thesis:

- Investors overly focused on the near-term slowdown and not focused on long term value.
- Their brands have lasted for centuries.
- Strong trends in premiumization create tailwinds. High ROIC business.
- Very low multiple and conservative DCF assumptions.
- 3% dividend yield, 1.5% share buy backs and 4.5% earnings growth for total return of 9%.



## Amazon (AMZN)



Target Price: \$213.02	Purchase Price: \$188.82
Beta: 1.15	P/E: 45.17
Stop Loss: 26%	Dividend Yield: 0%
Portfolio Allocation: 8%	ROIC: 13.24%

Performance: **+16%**  
Pitch Date: Oct. 7<sup>th</sup>, 2024  
Voting Results: 11/11, Buy  
Analysts: Kevin Jankowski, Adrien Vincent

#### Investment Thesis:

- **Revenue Growth:** DCF forecasts sales growth to stabilize at 10% in the next few years, driven by AWS, advertising, and international e-commerce.
- **Cost Efficiency:** Amazon aims to maintain a 50-55% gross margin by optimizing cost of revenue and leveraging economies of scale.
- **ROIC vs. WACC:** Amazon delivers a strong ROIC of 13.24%, well above its WACC of 8.26%, signaling efficient capital allocation and strong return potential.
- **Key Drivers:** AWS and advertising are expected to drive high-margin growth, further expanding profitability.



## Zoetis Inc. (ZTS)



Target Price: \$ 222	Purchase Price: \$ 242.73
Beta: 0.89	P/E: 35.2
Stop Loss: 18.69%	Dividend Yield: 1%
Portfolio Allocation: 6%	ROIC: 22.19

Performance: **-18.5%**  
Pitch Date: Oct. 28<sup>th</sup>, 2024  
Voting Results: 11/11, Buy  
Analyst: Sam Aguilar, Adrien Vincent

#### Investment Thesis:

- **Diversified Portfolio:** Strong in both pet and livestock sectors.
- **High ROIC (22.19%):** Efficient capital use, strong profitability.
- **Innovation-Driven:** Consistent R&D investment supports growth.
- **Global Expansion:** Opportunities in emerging markets.
- **Attractive Valuation:** 20-22% margin of safety



## The Hershey Company (HSY)



Target Price: \$217	Purchase Price: \$178.5
Beta: 0.37	P/E: 19.31
Stop Loss: 20%	Dividend Yield: 3.14%
Portfolio Allocation: 6%	ROIC: 24.65

Performance: **-19.2%**  
Pitch Date: Nov. 11<sup>th</sup>, 2024  
Voting Results: 11/11, Buy  
Analyst: Kevin Jankowski, Tim Cone

#### Investment Thesis:

- **Diversified Portfolio and Cost Efficiency:** diverse product lineup with a stronghold in North America. Aims to maintain a ~45% gross margin by optimizing the cost of revenue and leveraging economies of scale.
- **Wide Economic Moat:** Dominates the U.S. chocolate market with iconic brands like Reese's, Hershey's, and Kit Kat, enjoying significant brand loyalty.
- **ROIC vs. WACC:** ROIC of 24.65%, substantially higher than its WACC of 6.19%, reflecting efficient capital allocation and strong return potential.
- **Innovation-Driven:** Focused on product innovation and expansion into high-growth snack categories, with initiatives targeting health-conscious products.
- **Global Reach:** Hershey continues to expand internationally while solidifying its leading position in the North American market.



## Charles River Laboratories (CRL)



Target Price: \$185.40	Purchase Price: \$155.92
Beta: 1.45	P/E: 20.45x
Stop Loss: 35.5%	Dividend Yield: 0%
Portfolio Allocation: 4%	ROIC: 9.43%

Performance: **-36%**  
Pitch Date: Feb 10<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Kevin Adrien Vincent, Sam Aguilar

#### Investment Thesis:

- **Market Leadership in Preclinical Research & Strong Competitive Position**
  - CRL dominates the preclinical CRO space, a sector critical for biotech and pharmaceutical drug development.
  - It provides end-to-end services, from early discovery to safety assessment, reducing clients' time-to-market.
  - 90% client retention rate and 7.3 years average client relationship duration highlight its competitive moat.
- **Growth Catalysts & Expansion Opportunities**
  - **Logics:** CRL's AI-powered drug discovery platform (a collaboration with Vaini Health), is revolutionizing early-stage drug development.
  - **30% success rate in producing advanceable lead series.** Accelerated drug discovery reduces development timelines by 30-50%, creating a strong competitive advantage.
- **Expansion into Cell & Gene Therapy (High-Growth Sector)**
  - The cell and gene therapy market is projected to reach \$50B+ by 2030.
  - CRL's acquisition of Cognate Bio Services strengthens its biological, viral vector, and cell therapy offerings.
- **Increased Outsourcing of Pharma R&D**
  - Big Pharma is outsourcing over 50% of its R&D to CROs to cut costs and accelerate drug development.
- **Strategic M&A Activity & Geographic Expansion**
  - The track record of acquisitions (Vivox, AptTech's CRO assets, Clontech, Cognate BioServices) strengthens CRL's service portfolio.
  - The company is **severely undervalued**, which will allow for a significant growth potential.



## Schlumberger N.V (SLB)



Target Price: \$55	Purchase Price: \$42.94
Beta: 1.12	P/E: 12.9x
Stop Loss: 18%	Dividend Yield: 2.73%
Portfolio Allocation: 2%	ROIC: 11.78

Performance: **-18%**  
Pitch Date: Feb 17<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Kathryn Berger, Nathaly Herrera

#### Investment Thesis:

- **Market Leader:** SLB is the world's largest oilfield services provider, offering end-to-end solutions across the energy lifecycle.
- **Growth Focus:** Prioritizing core services, digital innovation, and new energy solutions to capitalize on industry trends.
- **Diversified Revenue:** Operates across four segments in 100+ countries, reducing market risk while expanding into low-carbon and digital services.
- **Tech Advantage:** AI and digital advancements drive efficiency and strengthen SLB's competitive edge.
- **Margin of Safety (MOS):** SLB has a 31.69% MOS, providing a strong downside cushion and attractive risk-reward potential.



## Adobe INC. (ADBE)



Target Price: \$510	Purchase Price: \$439.16
Beta: 1.49	P/E: 23.73x
Stop Loss: 20%	Dividend Yield: 0%
Portfolio Allocation: 4%	ROIC: 30.16

Performance: **-20%**  
Pitch Date: Feb 10<sup>th</sup>, 2025  
Voting Results: 11/11, Buy  
Analyst: Allen Counts, Mitchell Velasco

#### Investment Thesis:

- **Market Leadership and Comprehensive Product Suite:** Adobe Inc. stands as a global leader in digital media and marketing solutions, offering a comprehensive suite of products that cater to creative professionals, enterprises, and consumers. Its flagship offerings, such as Creative Cloud, Document Cloud, and Experience Cloud, have become industry standards, reinforcing Adobe's dominant market position.
- **Robust Financial Performance:** In fiscal year 2024, Adobe reported record revenues of \$21.5 billion, marking an 11% year-over-year growth. The Digital Media segment, encompassing Creative Cloud and Document Cloud, contributed \$15.9 billion, a 12% increase from the previous year. Notably, Creative Cloud revenue grew by 10% to \$12.68 billion, while Document Cloud revenue surged by 18% to \$3.18 billion.
- **Recurring Revenue Model:** Adobe's transition to a subscription-based model (95% of revenues) has resulted in a stable and predictable revenue stream. As of November 29, 2024, the company achieved a total Digital Media Annualized Recurring Revenue (ARR) of \$17.33 billion, reflecting a \$2 billion increase from the prior year.
- **Strong Customer Retention and Expansion:** Adobe's products are deeply embedded in the workflows of creative professionals and enterprises, leading to high customer retention rates (over 92%).

